Mucinous Tubular and Spindle Cell Carcinoma: Case Report and Literature Review.

IF 1.9 Q3 ONCOLOGY Journal of Kidney Cancer and VHL Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI:10.15586/jkc.v12i1.354
S L Tsang, S S Hsu, Cheung An, Shb Ho, Atl Ng
{"title":"Mucinous Tubular and Spindle Cell Carcinoma: Case Report and Literature Review.","authors":"S L Tsang, S S Hsu, Cheung An, Shb Ho, Atl Ng","doi":"10.15586/jkc.v12i1.354","DOIUrl":null,"url":null,"abstract":"<p><p>Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare type of renal cell carcinoma (RCC) recognized as an independent entity in the latest WHO (World Health Organization) classification. We here report a case of a 51-year-old female patient with MTSCC, who presented with abdominal pain and left lower pole kidney lesion on the computed tomography scan. A robotic-assisted laparoscopic partial nephrectomy was performed. The diagnosis was confirmed on histopathological examination. MTSCC is rare and generally indolent. Either partial or radical nephrectomy is usually curative. The prognosis is usually favorable. However, occasionally, MTSCC could demonstrate aggressive features requiring systemic therapy. There are also several mimickers of MTSCC, which carry different prognostic and treatment profiles. Histological, immunohistochemical, and molecular genetic profile are useful in diagnosing the disease.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"12 1","pages":"6-11"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870379/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Kidney Cancer and VHL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15586/jkc.v12i1.354","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare type of renal cell carcinoma (RCC) recognized as an independent entity in the latest WHO (World Health Organization) classification. We here report a case of a 51-year-old female patient with MTSCC, who presented with abdominal pain and left lower pole kidney lesion on the computed tomography scan. A robotic-assisted laparoscopic partial nephrectomy was performed. The diagnosis was confirmed on histopathological examination. MTSCC is rare and generally indolent. Either partial or radical nephrectomy is usually curative. The prognosis is usually favorable. However, occasionally, MTSCC could demonstrate aggressive features requiring systemic therapy. There are also several mimickers of MTSCC, which carry different prognostic and treatment profiles. Histological, immunohistochemical, and molecular genetic profile are useful in diagnosing the disease.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
粘液管状和梭形细胞癌:1例报告及文献复习。
粘液管状和梭形细胞癌(MTSCC)是一种罕见的肾细胞癌(RCC)类型,在最新的WHO(世界卫生组织)分类中被认为是一个独立的实体。我们在此报告一例51岁的MTSCC女性患者,她在计算机断层扫描上表现为腹痛和左肾下极病变。进行机器人辅助腹腔镜部分肾切除术。经组织病理学检查确诊。MTSCC是罕见的,通常是惰性的。部分或根治性肾切除术通常是可治愈的。预后通常是良好的。然而,偶尔,MTSCC可能表现出需要全身治疗的侵袭性特征。还有几种MTSCC的模拟物,它们具有不同的预后和治疗概况。组织学,免疫组织化学和分子遗传谱对诊断疾病有用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
6.20%
发文量
22
审稿时长
4 weeks
期刊最新文献
Advancing Minimally Invasive Surgery: Robotic Adrenalectomy for Pheochromocytoma-Efficacy, Safety, and Cost-Effectiveness in Focus. Imaging Characteristics of Pediatric Renal Cell Carcinoma and Wilms Tumor and Its Impact on Their Management and Outcomes-A Case Report and Review of Literature. Zinc as a Dual-Condition Inhibitor of HIF-1α/VEGF-α-Mediated Angiogenesis in Clear Cell Renal Carcinoma. Body Composition May Be a Novel Presurgical Risk Factor for Acute Kidney Injury among Clear Cell Renal Cell Cancer Patients Undergoing Radical Nephrectomy. Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1